Advertisement

PentaVision

Glaucoma Physician

Article | 2025 American Glaucoma Society Meeting

AGS Recommends Cautious Approach to Nicotinamide

Although nicotinamide, an over-the-counter supplement, remains intriguing as a potential neuroprotective agent for glaucoma, more research is needed to verify its long-term safety at higher doses.

Jim Gallagher, senior managing editor
Glaucoma Physician March 4, 2025
5 Key Takeaways

  • 1

    The American Glaucoma Society recommends caution regarding nicotinamide supplementation for glaucoma due to safety concerns.

  • 2

    High doses of nicotinamide (≥3 g/day) have shown potential benefits in early human trials but pose risks of liver toxicity.

  • 3

    Two cases of drug-induced liver injury were reported in trials, highlighting serious risks associated with high-dose nicotinamide.

  • 4

    Nicotinamide is not approved as a glaucoma treatment, and its long-term safety remains uncertain.

  • 5

    AGS and AAO emphasize the need for more research before endorsing nicotinamide as a neuroprotective agent for glaucoma.